Dr.Kamini Silvarajan MD/AAAM

Editorial Board: Dr.Kamini Silvarajan MD/AAAM

Allergic Asthma Intramuscular Vaccine

Bronchial asthma is a chronic inflammatory disease that affects the bronchial tubes and bronchioles in the lungs. Moreover, this condition is caused by several factors including allergens. Allergens are referred to substances that are commonly present in the external environment. This type of pathogen can cause mild to severe irritation to the airway, which may lead to inflammatory process.

Due to this scenario, several clinical practitioners are developing a treatment scheme to prevent these allergens from causing inflammatory processes in the airway. Furthermore, this study proves to be one of the highly-structure approaches that can be developed.

Based on the publication review from Human Gene Therapy, their specialists have established a clinical research. This research had revealed an innovative intramuscular vaccine that can fight against these allergens.

The study was conducted through a clinical investigation. The experimented vaccine was used to an asthmatic mouse. It was injected intramuscularly. The result shows that the asthmatic mouse had significantly improved its condition from the hypersensitivity reaction to allergen.

Current Case Report for Allergic Bronchial Asthma

Below are the recent reported morbidities of allergic bronchial asthma based on WHO (World Health Organization) health portfolio: 

  1. Allergic bronchial asthma has affected more than 300 million of individuals worldwide.
  2. The cases of asthma were doubled for over 1 year.
  3. Additional 250,000 cases of allergic bronchial asthma were reported in U.S. alone.
  4. 5.4 out of 10 individuals are dying from premature allergic bronchial asthma attack in a day.
  5. Developed countries have more morbidity cases of allergic asthma compare to underdeveloped and developing countries.
  6. Urban areas are at 50% higher risk of suffering from allergic asthma compare to rural areas.
  7. Cases of allergic bronchial asthma to men are doubled compared to women (ratio of 2:1).
  8. Allergic bronchial asthma is common to children ages 4 to 10 years old. 

New Vaccine Mechanism of Action

Currently, the treatment used for allergic asthma is corticosteroids. However, this medication works to relive the signs and symptoms of asthma but it does not cure the health problem. The recent developed intramuscular vaccine for allergic asthma uses the method of desensitization.

It is also known as immunotherapy. It means that a certain allergen is introduced to the body through a form of vaccine. Repeated doses on deactivated allergen to the body can help the immune system to build up resistance against these allergens.

The dosages are given repeatedly to reduce the risk of developing allergic bronchial asthma. However, the issue pertaining to the development of this vaccine has been limited. The mechanism of action of the vaccine may vary from one person to another. Clinical tests were done to different people with allergic asthma.

Each person who received the vaccine had shown different reactions. This issue had led the clinical practitioners to research more on engineering the vaccine using the DNA of the specific allergen. The study had pushed the team to stop using the repetitive approach. Instead, they focused on alternating the DNA structure of the allergen, which causes inflammatory processes to the airway.

However, this scenario was not been applied to human experimentation. According to Bruno Pitard, Director of Biotherapy Innovations, he mentioned the need for further studies, which can help explain the therapeutic effect of the vaccine using the new approach. He also mentioned the need to conduct human experimentation with regards to its testability and effectiveness.

Today, the issue related to DNA restructuring of allergen as applicable for human consumption; is still under the preclinical trial. This new method is being developed until final analysis will be established for future use– By Edterchelle Soriano